Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Company Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe
Other stock markets
 01:28:35 13/06/2024 pm IST 		5-day change 1st Jan Change
1,846 DKK -0.04% Intraday chart for Genmab A/S -5.15% -14.59%
10/06 Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
04/06 Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT

Business Summary

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:

- royalties (83.2%);

- income from research and development (12.4%);

- other (4.4%): primarily income from partnership agreement.

At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.

Denmark accounts for all net sales.

Number of employees: 2,286

Sales per Business

DKK in Million2022Weight2023Weight Delta
Antibody Therapeutics
100.0 %
14,595 100.0 % 16,474 100.0 % +12.87%

Sales per region

DKK in Million2022Weight2023Weight Delta
Denmark
97.4 %
14,595 100.0 % 16,053 97.4 % +9.99%
United States
2.3 %
0 0.0 % 380 2.3 % -
Japan
0.2 %
0 0.0 % 41 0.2 % -

Managers

Managers TitleAgeSince
Jan van de Winkel CEO
 Chief Executive Officer 63 01/99/01
Anthony Pagano DFI
 Director of Finance/CFO 46 01/07/01
Anthony Mancini COO
 Chief Operating Officer 53 23/20/23
Tahamtan Ahmadi CTO
 Chief Tech/Sci/R&D Officer 51 01/17/01
Marisol Peron IRO
 Public Communications Contact - 11/19/11
Christopher Cozic HRO
 Human Resources Officer 46 -
Judith Klimovsky PRN
 Corporate Officer/Principal 67 09/17/09
Martine van Vugt PRN
 Corporate Officer/Principal 71 01/01/01
Birgitte Stephensen LAW
 General Counsel 63 01/02/01

Members of the board

Members of the board TitleAgeSince
Deirdre Connelly CHM
 Chairman 63 01/17/01
Anders Gersel Pedersen BRD
 Director/Board Member 73 01/03/01
Rolf K. Hoffmann BRD
 Director/Board Member 64 01/16/01
Elizabeth O'Farrell BRD
 Director/Board Member 59 29/22/29
Pernille Erenbjerg BRD
 Director/Board Member 57 01/15/01
Paolo Augusto Paoletti BRD
 Director/Board Member 73 01/15/01
Mijke Zachariasse BRD
 Director/Board Member 51 29/19/29
Martin Schultz BRD
 Director/Board Member 49 01/22/01
Takahiro Hamatani BRD
 Director/Board Member 50 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,129,923 65,143,457 ( 98.51 %) 981,465 ( 1.484 %) 98.51 %

Shareholders

NameEquities%Valuation
Wellington Management Co. LLP
4.895 %
3,237,113 4.895 % 913 M kr
GENMAB A/S
2.845 %
1,881,559 2.845 % 530 M kr
Jan van de Winkel
0.9081 %
600,497 0.9081 % 169 M kr
Nykredit Bank A/S (Investment Management)
0.4632 %
306,295 0.4632 % 86 M kr
Amundi Asset Management SA (Investment Management)
0.3155 %
208,668 0.3155 % 59 M kr
Danske Bank A/S (Investment Management)
0.2283 %
150,968 0.2283 % 43 M kr
Robert W. Baird & Co., Inc. (Equity)
0.1861 %
123,067 0.1861 % 35 M kr
State Street Global Advisors Ltd.
0.1695 %
112,073 0.1695 % 32 M kr
Sjunde AP-fonden
0.1444 %
95,465 0.1444 % 27 M kr
S.W. Mitchell Capital LLP
0.1353 %
89,501 0.1353 % 25 M kr
NameEquities%Valuation
AllianceBernstein LP
2.307 %
15,254,347 2.307 % 430 M kr
BlackRock Advisors LLC
0.7590 %
5,019,269 0.7590 % 142 M kr
Capital Research & Management Co. (International Investors)
0.6613 %
4,373,277 0.6613 % 123 M kr
Harding Loevner LP
0.4982 %
3,294,728 0.4982 % 93 M kr
Wellington Management Co. LLP
0.3526 %
2,331,814 0.3526 % 66 M kr
RBC CMA LLC
0.2732 %
1,806,502 0.2732 % 51 M kr
Renaissance Technologies LLC
0.2054 %
1,358,600 0.2054 % 38 M kr
Wells Fargo Bank NA
0.1930 %
1,276,518 0.1930 % 36 M kr
First Trust Advisors LP
0.1859 %
1,229,570 0.1859 % 35 M kr
U.S. Trust Company of Delaware
0.1677 %
1,109,117 0.1677 % 31 M kr

Holdings

NameEquities%Valuation
GENMAB A/S
2.85%
 1,881,559 2.85% 530,452,462 $

Company contact information

Genmab A/S

Carl Jacobsens Vej 30 Valby

2500, Copenhagen

+45 70 20 27 28

http://www.genmab.com
address Genmab A/S(GMAB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,847 DKK
Average target price
2,464 DKK
Spread / Average Target
+33.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GENMAB A/S Stock Genmab A/S
-14.59% 1.73TCr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.93% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+17.01% 11TCr
BIONTECH SE Stock BioNTech SE
-7.23% 2.36TCr
ARGENX SE Stock argenx SE
+3.06% 2.26TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.79% 1.76TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.63% 1.76TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.17% 1.35TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+24.42% 1.13TCr
INSMED INCORPORATED Stock Insmed Incorporated
+98.94% 993.96Cr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. Company Genmab A/S